EP
CLVS

Eversept Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Eversept Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$60.6K – 104
2022
Q1 		$60.6K Buy
+30,000
New +$58.9K ﹤0.01% 86
2018
Q1 		– Sell
-16,397
Closed -$1.11M – 63
2017
Q4 		$1.11M Buy
+16,397
New +$1.15M 0.64% 30

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Eversept Partners's CLVS Position: Q2 2022 in Review

Eversept Partners sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 30,000 shares — an estimated $60.6K sold.

Eversept Partners first reported a position in CLVS in Q4 2017 and held it in 2 quarters. The position peaked at $1.11M in Q4 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

  • Eversept Partners reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
  • Eversept Partners sold 30,000 Clovis Oncology, Inc. shares in Q2 2022, an estimated $60.6K.
  • Eversept Partners first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 2 quarters.
  • Eversept Partners's Clovis Oncology, Inc. position peaked at $1.11M in Q4 2017.
  • 115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.